What is a common management option for myasthenia gravis?

Pyridostigmine bromide is a first-line treatment option for myasthenia gravis because it acts as a reversible acetylcholinesterase inhibitor. This medication works by preventing the breakdown of acetylcholine at the neuromuscular junction, leading to increased levels of acetylcholine available to stimulate the postsynaptic receptors. As a result, pyridostigmine facilitates better communication between nerves and muscles, improving muscle strength in individuals affected by this autoimmune disorder.

While other treatment options, such as intravenous immunoglobulin, corticosteroids, and rituximab, are also used in the management of myasthenia gravis, they serve different roles. Corticosteroids can help reduce inflammation and suppress the immune system's response but are typically considered when symptoms are more severe or when rapid symptom control is necessary. Intravenous immunoglobulin can provide temporary improvement in muscle strength by modifying the immune system's activity. Rituximab, a monoclonal antibody, is often employed in cases of refractory myasthenia gravis or for those who do not respond to conventional therapies.

The choice of pyridostigmine as a common management option reflects its foundational role in enhancing neuromuscular transmission